Deals
AstraZeneca to Buy Respiratory Drug Business From Japan's Takeda
- Drugmaker to buy respiratory business from Japan's Takeda
- AstraZeneca also strikes deal with China's WuXi AppTec
This article is for subscribers only.
AstraZeneca Plc announced two transactions designed to beef up its operations in China and Japan, where sales are growing.
The London-based drugmaker agreed to buy a respiratory business from Japan’s Takeda Pharmaceutical Co. for $575 million to gain global rights to the lung treatment roflumilast, according to a statement on Wednesday. It also struck an alliance with China’s WuXi AppTec, a research and development platform, to investigate biological medicines.